Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Nov 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage pain for patients who have ureteral stents after a procedure called ureteroscopy, which is used to treat kidney stones. The researchers want to see if a medication called intra-nasal ketorolac, which is sprayed into the nose, can help reduce pain more effectively and quickly than a commonly used oral pain reliever called diclofenac. The goal is to improve the quality of life for patients who experience discomfort from these stents.

To participate in the trial, you need to be at least 18 years old, speak English, and be scheduled for a ureteroscopy that includes placing a ureteral stent. Unfortunately, some people may not be eligible, such as those who are pregnant, have certain kidney issues, or have had complications with stents in the past. If you join the study, you can expect to receive either the nasal spray or the oral medication and share your experiences about how well your pain is managed. This research aims to make recovery easier and reduce the need for extra doctor visits due to pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years old
• • English-speaking
• • Candidate for unilateral ureteroscopy for treatment of urolithiasis
• • Surgical plan includes placement of a ureteral stent
• Exclusion Criteria:
• • Pregnant/nursing, prisoners, cognitively impaired
• • Solitary kidney
• • Stone in transplant kidney
• • Anatomic abnormalities (i.e., ureteral stricture, infundibular stenosis, uretero-pelvic junction obstruction, horseshoe kidney, duplicated system)
• • History of ureteral reconstruction
• • History of nephrocalcinosis, medullary sponge kidney, cystinuria
• • Immobility or relative immobility
• • Planned staged ureteroscopy
• • History of ureteral stent complication or poor tolerance or a ureteral stent
• • Urinary tract infection or sepsis
• • Current anticoagulation use (81 mg Aspirin permissible)
• • NSAID contraindication (acute renal failure or chronic kidney disease, bleeding disorders, allergic reaction to NSAIDs, ulcer disease, auto-immune disease)